[go: up one dir, main page]

WO2006003587A3 - Solid oral dosage forms of azabicyclo derivatives - Google Patents

Solid oral dosage forms of azabicyclo derivatives Download PDF

Info

Publication number
WO2006003587A3
WO2006003587A3 PCT/IB2005/052104 IB2005052104W WO2006003587A3 WO 2006003587 A3 WO2006003587 A3 WO 2006003587A3 IB 2005052104 W IB2005052104 W IB 2005052104W WO 2006003587 A3 WO2006003587 A3 WO 2006003587A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
oral dosage
solid oral
solid dosage
azabicyclo derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/052104
Other languages
French (fr)
Other versions
WO2006003587A2 (en
Inventor
Korlapati Venkateswara Rao
Pradeep Jai Rao Karatgi
Ayanampudi Sri Rama Murthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2006003587A2 publication Critical patent/WO2006003587A2/en
Publication of WO2006003587A3 publication Critical patent/WO2006003587A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to solid dosage forms for oral administration of an azabicyclo derivative or its pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs and metabolites; and processes for the preparation of such solid dosage forms. The solid dosage forms can be characterized as having excellent content uniformity.
PCT/IB2005/052104 2004-07-01 2005-06-24 Solid oral dosage forms of azabicyclo derivatives Ceased WO2006003587A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1234DE2004 2004-07-01
IN1234/DEL/2004 2004-07-01

Publications (2)

Publication Number Publication Date
WO2006003587A2 WO2006003587A2 (en) 2006-01-12
WO2006003587A3 true WO2006003587A3 (en) 2006-09-14

Family

ID=35124429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/052104 Ceased WO2006003587A2 (en) 2004-07-01 2005-06-24 Solid oral dosage forms of azabicyclo derivatives

Country Status (1)

Country Link
WO (1) WO2006003587A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006117754A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
RU2008119323A (en) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) PHARMACEUTICAL COMPOSITIONS OF THE MUSCARINE RECEPTOR
US20100152269A1 (en) * 2006-12-21 2010-06-17 Ranbaxy Laboratories Limited Modified-release formulations of azabicyclo derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005252A1 (en) * 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005252A1 (en) * 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists

Also Published As

Publication number Publication date
WO2006003587A2 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
WO2007135527A3 (en) Benzimidazolyl compounds
WO2006011050A3 (en) Pyridine derivatives
EP1740156B8 (en) Method for the production of an abuse-proof, solid form of administration
WO2007042035A3 (en) Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
UA84726C2 (en) Prostaglandin derivatives, process for the preparation thereof, pharmaceutical composition (variants) and method for the treatment of glaucoma and ocular hypertension
WO2007087548A3 (en) Chemical compounds
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2008027542A3 (en) 5-substituted isoindoline compounds
NZ602266A (en) Macrocycles as factor xia inhibitors
WO2008012622A3 (en) Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
MX2009008540A (en) Pyrimidine substituted macrocyclic hcv inhibitors.
WO2008006795A3 (en) Indole compounds
WO2010070449A3 (en) Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2005094810A3 (en) Novel pharmaceutical compositions
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
NO20080033L (en) Quinoline derivatives as NK3 antagonists
WO2007070433A3 (en) 2-arylthiazole derivatives as cxcr3 receptor modulators
WO2009056707A8 (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
WO2005105753A3 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
WO2008038092A3 (en) Substituted piperidinophenyl oxazolidinones
WO2004111047A3 (en) Cycloalkanepyrrolopyridines as dp receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 722/DELNP/2007

Country of ref document: IN

122 Ep: pct application non-entry in european phase